Zanzottera EC, Ach T, Huisingh C, Messinger JD, Spaide RF, Curcio CA: Visualizing retinal pigment epithelium phenotypes in the transition to geographic atrophy in age-related macular degeneration.

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces the first close of its ...

Apellis Pharma has become the first company to claim FDA approval for a drug to treat geographic atrophy ... the loss of photoreceptors and retinal pigment epithelial (RPE) cells, the central ...

The continued evolution of treatment protocols and imaging modalities for the management of retinal diseases offer ... for the management of geographic atrophy secondary to age-related macular ...

Certain imaging biomarkers and demographic factors are associated with geographic atrophy growth rate and may guide the selection of patients for the use of newer therapeutics. Share on Facebook.

Geographic atrophy is an advanced form of dry age-related macular degeneration that causes vision loss in older adults. Until recently, there were no treatments available to target the root cause.

However, GA involves more significant and irreversible loss of retinal tissue. Therefore, the difference between geographic atrophy and dry AMD lies in the severity and stage of the condition.

The phase 1b trial will enrol patients with geographic ... geographic atrophy – an advanced form of the disease characterised by the loss of photoreceptors and retinal pigment epithelial ...

and preserving the integrity of the retinal pigment epithelium, with the potential of preventing retinal degeneration and vision loss. Judith Greciet, CEO of PulseSight Therapeutics, said ...

PST-611-CT1 is a first-in-human single ascending dose trial aiming to confirm the favorable safety profile of the drug and validate the maximal dose for the Phase II proof-of-concept study, in six to ...